ArticlePharmaceutics2021
In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against
Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Flavonoids as a Potential Antifungal Alternative AgainstJournal of fungi (Basel, Switzerland) · 2026Article
- Evaluation of Antimicrobials Incorporated into Artificial Saliva: Analysis AgainstJournal of functional biomaterials · 2026Article
- Evaluation of the Synergistic Activity of Anidulafungin with Isavuconazole, Voriconazole, Posaconazole, and Amphotericin B inInfection and drug resistance · 2026Article
- The GPI-Anchored Aspartyl Proteases Encoded by theJournal of fungi (Basel, Switzerland) · 2025Article
- Intensification of Invasive Fungal Infections and Exploration of Effective Antifungal Drug Delivery Formulations: A Detailed Review.Infectious disorders drug targets · 2025Review
- Review
- Overcoming amphotericin B resistance inAntimicrobial agents and chemotherapy · 2024Article
- Synergistic action of synthetic peptides and amphotericin B causes disruption of the plasma membrane and cell wall in Candida albicans.Bioscience reports · 2024Article
- Efficacy of the combination of amphotericin B and echinocandins againstMicrobiology spectrum · 2024Article
- In Vitro Susceptibility Tests in the Context of Antifungal Resistance: Beyond Minimum Inhibitory Concentration inJournal of fungi (Basel, Switzerland) · 2023Review
- Critical appraisal beyond clinical guidelines for intraabdominal candidiasis.Critical care (London, England) · 2023Review
- Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida aurisAntimicrobial agents and chemotherapy · 2023Article
- In Vitro Killing Activities of Anidulafungin and Micafungin with and without Nikkomycin Z against FourPharmaceutics · 2023Article
- Navigating the New Reality: A Review of the Epidemiological, Clinical, and Microbiological Characteristics ofJournal of fungi (Basel, Switzerland) · 2023Review
- Strategies to Prevent Transmission ofCurrent fungal infection reports · 2023Review
- Small molecules for combating multidrug-resistant superbugActa pharmaceutica Sinica. B · 2022Review
- Synergism between the Antidepressant Sertraline and Caspofungin as an Approach to Minimise the Virulence and Resistance in the DermatophyteJournal of fungi (Basel, Switzerland) · 2022Article
- A Cecropin-4 Derived Peptide C18 InhibitsFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Treatment of invasive infections caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.